PatientsVille.com Logo

Insulin and Phentermine

PatientsVille

Insulin Symptoms and Causes

Diabetes means your blood glucose, or blood sugar, levels are too high. If you can't control your diabetes with wise food choices and physical activity, you may need diabetes medicines. The kind of medicine you take depends on your type of diabetes, your schedule, and your other health conditions.

With type 1 diabetes, your pancreas does not make Insulin. Insulin is a hormone that helps glucose get into your cells to give them energy. Without Insulin, too much glucose stays in your blood. If you have type 1 diabetes, you will need to take Insulin.

Type 2 diabetes, the most common type, can start when the body doesn't use Insulin as it should. If your body can't keep up with the need for Insulin, you may need to take pills. Along with meal planning and physical activity, diabetes pills help people with type 2 diabetes or gestational diabetes keep their blood glucose levels on target. Several kinds of pills are available. Each works in a different way. Many people take two or three kinds of pills. Some people take combination pills. Combination pills contain two kinds of diabetes medicine in one tablet. Some people take pills and Insulin.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for insulin

insulin treatment research studies

Phentermine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Phentermine Side Effects

Pain (28)
Dyspnoea (27)
Anxiety (26)
Chest Pain (22)
Deep Vein Thrombosis (20)
Nausea (19)
Abdominal Pain (18)
Headache (16)
Blood Pressure Increased (16)
Abdominal Pain Upper (16)
Mitral Valve Incompetence (15)
Cholelithiasis (15)
Cholecystitis Chronic (14)
Pulmonary Embolism (14)
Injury (13)
Vomiting (13)
Ventricular Fibrillation (13)
Myocardial Infarction (13)
Loss Of Consciousness (12)
Dizziness (12)
Colitis Ischaemic (11)
Cardiac Arrest (11)
Gallbladder Disorder (10)
Fatigue (10)
Insomnia (10)
Cerebrovascular Accident (9)
Hypertension (9)
Arteriospasm Coronary (9)
Palpitations (8)
Confusional State (8)
Chest Discomfort (7)
Convulsion (7)
Hypotension (7)
Emotional Distress (7)
Feeling Abnormal (7)
Asthenia (6)
Abnormal Behaviour (6)
Diarrhoea (6)
Pain In Extremity (6)
Hypoaesthesia (6)
Tricuspid Valve Incompetence (6)
Hypercoagulation (5)
Alanine Aminotransferase Increased (5)
Mental Disorder (5)
Heart Rate Increased (5)
Pneumomediastinum (5)
Ventricular Tachycardia (5)
Respiratory Arrest (5)
Pyrexia (5)
Migraine (5)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

after reading the above, I would like to share that My fbs dropped to 70 after shifting to hum insulin 30/70 from other make, where there is no control.I think it is better working for me.

59 year old male has had diabetis for almost 4 years has swollen feet and has gained 30 pounds after his doctor increased his insulin intake but my numbers are down so I guess iuts a give and take situation is there any thing I can do about these sid

I also nap quite a lot i seems I am sleeping my life away dave

I am taking huminsulin 15 units at morning lunch and at night . Inaddition 10 units lantus before to bed but suger level become up and down sometimes fasting from 140 to 230 and ppbs at 330 to 400. I would like to know that why it is not balancing

I am taking huminsulin 20 units at morning and 16 units at night but suger level become up and down sometimes fasting from 140 to 230 and ppbs at 290 to 440. I would like to know that why it is not balancing? And after consulting my Doctor I have cha

I am taking Huminsulin 50/50 Before breakfast 36 U and 14 U before dinner and after breakfast Vidagliptin 50 with Metformin 500. Dosage is OKay?

I am taking huminsulin from this site and its not working.

I BELIEVE I WAS DRUGGED WITH INSULIN I FELT EXTREMELY TIRED AND WENT TO SLEEP FOR A LITTLE WHILE TO HAVE BEEN WOKEN UP BY THE NEED TO VOMIT

I need wholesale humulin injection I need how to contact you and i need full information

Iam 26 years old lady taking 28 unit in morning and 18 units in night but not so effective

after reading the above, I would like to share that My fbs dropped to 70 after shifting to hum insulin 30/70 from other make, where there is no control.I think it is better working for me.

i took my insulin at 10pm about 1130 i started to black out get dizzy confused sweating took my readind at 4pm it was 247

<b>Describe I was put on Deplin 15mg to supplement the antidepressent that I have been on for for 3wks now. This was just 2 days ago. I feel a little better, but I am an insulin dependent diabetic, and my sugars have actually gone up to

59 year old male has had diabetis for almost 4 years has swollen feet and has gained 30 pounds after his doctor increased his insulin intake but my numbers are down so I guess iuts a give and take situation is there any thing I can do about these sid

Addition- I was hospitalized in Bermuda, March 20 - 25/10, after spending evening of 19th., in E.R. with B.G. 448. Hydrated with N/Saline. Insulin commenced. Hyzaar D/C because of Diuretic.All tests neg., so far!&nbs

After the kidney transplant my daughter's glucouse level was very high due to tacrolimus At the moment she takes insulin I want to know that the damage tacrolimus was done for the beta cells are permanant? little by little the units she takes reducin

Been on the insulin since last year. ever since then i have been experiencing headaches, tiredness and even hair loss to the point where i am to scared to even brush my hair!

I am 29 yrs & i am a diabetic patient for last 4 yrs. For last two months i have been put on Galvus Met 50mg/850mg by stopping 3 times insulin. Its really effective & i couldn't experience any major side effects.Most important thing i

I am 34 years old guy and using insulin Insulatard and Actrapid for the last 9 years. I found no side effects for me. And I am not taking any other medicines.

I am a <b>Cancer patient with Diabetes Type 2 and dependent on Human Insulin for many years. I am on Insulin on two times a day. I was on chemotherapy several times and many cycles. My sugar level is still unconrolled.&n

Insulin Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Regulation of Endogenous Glucose Production by Brain Insulin Action
Condition: Insulin Resistance, Diabetes
Intervention: Drug: Intranasal Insulin
Outcome Measure: Endogenous glucose production
2 Recruiting Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes
Condition: Diabetes During Pregnancy
Interventions: Drug: NPH;   Drug: Insulin LISPRO;   Drug: Insulin glulisine
Outcome Measures: show that Insulin glulisine is non-inferior to Insulin lispro in a basal/bolus regimen to treat hyperglycemia in patient with gestational diabetes mellitus;   Serum blood glucose area under the curve (AUC) at one 4-hour in-clinic meal challenge;   Compare A1C at enrollment and weekly until delivery;   Compare incidence of hypoglycemic episodes <60 mg/dL with symptoms
3 Unknown  The Effect of Central Insulin on Insulin Sensitivity and Energy Metabolism
Condition: Diabetes
Interventions: Drug: central Insulin;   Drug: Placebo
Outcome Measures: Insulin sensitivity;   Energy metabolism
4 Not yet recruiting PK/PD STUDY OF U-500 REGULAR Insulin
Conditions: Type 2 Diabetes;   Insulin Resistance;   High Insulin Requirements
Intervention: Drug: U-500 Insulin
Outcome Measures: Duration (in hours) of 20 % dextrose infusion requirement;   Peak 20 % dextrose requirement.;   Area under the curve (AUC) of 20 % dextrose
5 Not yet recruiting A Study to Compare and Measure the Effects of Insulin Peglispro and Glargine on Meal Time Insulin Requirements
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Insulin Peglispro;   Drug: Insulin Lispro;   Drug: Insulin Glargine
Outcome Measures: Pharmacodynamics: Plasma Glucose Area Under the Concentration Curve (AUC), Above Pre Meal Baseline for Insulin Lispro;   Pharmacokinetics: Area Under the Concentration Curve (AUC) for Prandial Insulin Lispro;   Pharmacodynamics: Average Glucose Infusion Rate from Euglycemic 2-step HyperInsulinemic Clamp (M-value);   Pharmacokinetics: Area Under the Concentration Curve (AUC) for Paracetamol;   Appetite and Satiety Ratings, as Measured Using Visual Analog Scale (VAS);   Pharmacodynamics: Area Under the Concentration Curve for Triglyceride;   Pharmacokinetics: Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp
6 Not yet recruiting The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
Conditions: Diabetes Mellitus, Type 2;   Diabetes
Interventions: Drug: Metformin;   Drug: Detemir;   Drug: Liraglutide;   Drug: Insulin Aspart
Outcome Measures: Composite end-point;   Mean change from randomization in A1c at week 26;   Percentage of patients reaching target A1c of <7% at week 26;   Percentage of patients reaching pre-specified "treatment failure" outcome;   Mean change from randomization in body weight;   Percentage of patients who lost 5% or more of body weight from randomization;   Hypoglycemic episodes;   Percentage of patients experiencing any hypoglycemic episode;   Diabetes Quality of Life (DQOL)questionnaire score;   Short Form-36 (SF-36) questionnaire score;   Number of daily injections;   Health care cost, total;   Health care cost, diabetes-related;   Number of titration events by healthcare professional;   Number of titration events by patient;   Healthcare provider time during scheduled office (minutes/visit);   Healthcare provider time, unscheduled (total minutes);   Compliance with pharmacologic therapy;   Change in LDL cholesterol from baseline to week 26;   Change in triglycerides from baseline;   7-point glucose profiles over 2 consecutive days
7 Unknown  Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: Gliclazide MR and Insulin Glargine Injection;   Drug: Biosynthetic Human Insulin Injection
Outcome Measures: Decreasing value of FPG and HbA1c, dosage of Insulin and control rate of FPG;   MBG, SDBG, MAGE and MODD in the 48th CGMS;   Incidence of hypoglycemia and severe hypoglycemia;   Weight change
8 Unknown  PK/PD Study of Intranasal Insulin in Type I Diabetes
Condition: Type 1 Diabetes
Interventions: Drug: Insulin;   Drug: Insulin LISPRO
Outcome Measure: Insulin tolerability, PK, and PD
9 Recruiting Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Saxagliptin 5mg;   Drug: Placebo for Saxagliptin
Outcome Measures: The change in glycosylated hemoglobin A1c (HbA1c) from baseline to Week 24 (prior to rescue/censoring);   The change from baseline to Week 24 (prior to rescue/censoring) in the postprandial plasma glucose (PPG) area under the curve (AUC) from 0 to 180 minutes in response to a meal tolerance test;   The change from baseline to Week 24 (prior to rescue/censoring) in 120-minute postprandial plasma glucose (PPG) in response to a meal tolerance test;   The proportion of subjects achieving a therapeutic glycaemic response at Week 24 (prior to rescue/censoring) defined as HbA1C <7%;   The change from baseline to the mean of Weeks 20 and 24 (prior to rescue/censoring) in fasting plasma glucose (FPG);   The change in mean total daily dose of Insulin (MTDDI) from baseline to Week 24 (regardless of rescue/censoring)
10 Recruiting Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia
Condition: Post-Transplant Glucocorticoid Induced Diabetes
Interventions: Drug: Neutral protamine hagedorn (NPH) Insulin;   Drug: Regular human Insulin or Insulin Aspart;   Drug: Insulin glargine
Outcome Measures: Blood glucose - inpatient;   Post prandial blood glucose - inpatient;   Length of inpatient hospital stay;   Blood glucose;   Hemoglobin A1C;   Post prandial blood glucose;   Hypoglycemic episodes;   Glycemic treatment failure;   Cardiovascular events;   Post-transplant infections or new antibiotic use;   Transplant graft failure;   New acute renal failure;   Mortality
11 Recruiting Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: Intermittent Insulin therapy;   Drug: Continuous metformin
Outcome Measures: Baseline-adjusted beta-cell function at 2 years, measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2).;   Baseline-adjusted glycemic control at 2-years.
12 Recruiting Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation
Condition: Hyperglycemia
Interventions: Drug: Insulin lispro, Humalog (Eli Lilly) in Insulin pump;   Drug: Human Insulin isophane, Humulin N (Eli Lilly);   Other: Standard of care
Outcome Measures: Glycosylated hemoglobin (HbA1c);   Oral glucose tolerance test (OGTT)-derived 2 hour-glucose;   Fasting glucose;   Beta cell function;   Insulin sensitivity;   Daily glucose measurements;   Serum creatinine
13 Not yet recruiting Cystic Fibrosis (CF) Exacerbation and Insulin Treatment
Conditions: Cystic Fibrosis;   Impaired Glucose Tolerance;   Pulmonary Exacerbation
Interventions: Drug: novorapid / humalog short acting Insulin;   Drug: Novo Rapid Insulin (Novonordisk)
Outcome Measures: delta Forced Expiratory Volume in 1 second (FEV1%) predicted;   change in Body Mass Index (BMI)
14 Unknown  Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use
Condition: Insulin-requiring Type 2 Diabetes Mellitus
Interventions: Drug: nph Insulin;   Drug: human Insulin;   Drug: Insulin Glargine;   Drug: Insulin glulisine
Outcome Measures: Fasting Intact ProInsulin;   Weight;   hsCRP;   Adiponectin;   MMP-9;   OGTT parameters (Insulin, intact proInsulin, glucose at time point 0, 60 and 120 minutes after 24 weeks;   HOMA-IR score;   HbA1c;   Fasting intact ProInsulin;   Glucose;   Responder rate;   Hypoglycemic events.
15 Unknown  Glucose Insulin Potassium With Intensive Insulin Therapy and (GIK2) Versus GIK Alone
Condition: Acute Coronary Syndrome
Interventions: Drug: glucose Insulin potassium;   Drug: GIK and intensive Insulin therapy
Outcome Measures: 30 days mortality, reinfarction, urgent coronary revascularisation, and stroke.;   Severe dysrhythmias, acute left ventricular failure with ejection fraction<45%, change of serum B-type natriuretic peptide (BNP), serum troponin, and platelet factor activator (PFA-100) within 24 hours after the start of protocol treatment.
16 Recruiting Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy
Conditions: Diabetes, Gestational;   Diabetes, Type 2
Intervention: Drug: Insulin
Outcome Measures: glycemic control;   Percentage of patients obtaining glycemic control;   Time to achieve glycemic control;   Average fasting glucose;   Post-prandial blood glucose;   Weight gain;   Neonatal weight;   Gestational age at delivery;   Maternal Hypoglycemia;   Neonatal bilirubin;   Intensive care admissions;   Delivery Mode;   Birth rate;   Shoulder dystocia;   Polyhydramnios;   Neonatal hypoglycemia
17 Recruiting Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.
Conditions: Diabetes Mellitus Type I;   Ketoacidosis
Interventions: Drug: Insulin withdrawal;   Drug: Norditropin
Outcome Measures: Insulin and growth hormone signalling, expressed as CHANGE in phosphorylation of intracellular target proteins and CHANGE in mRNA expression of target genes in muscle- and fat-tissue.;   Change in Intracellular markers of lipid metabolism in muscle- and fat tissue biopsies.;   Metabolism
18 Recruiting A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: Insulin degludec/liraglutide;   Drug: Insulin aspart
Outcome Measures: Change from baseline in HbA1c (glycosylated haemoglobin);   Change from baseline in body weight;   Number of treatment-emergent confirmed hypoglycaemic episodes
19 Unknown  Comparing Long-acting Insulins During Exercise in Type 1 Diabetes
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Insulin glargine;   Drug: Insulin detemir
Outcome Measures: Glucose excursion (which, as defined below, is the change in blood glucose between the start and finish of one hour of exercise);   Lactate;   NEFA (Non-esterified fatty acids);   B-OHB (beta-hydroxybutyrate);   Catecholamines;   Glucagon;   Human growth hormone (hGH);   Cortisol;   IL-6 (interleukin 6);   High sensitivity CRP (Hs-CRP);   RQ (Respiratory Quotient);   Frequency of hypoglycaemic events;   Time spent in hypoglycaemia;   Blood glucose
20 Recruiting Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
Condition: Type 2 Diabetes
Interventions: Drug: lixisenatide (AVE0010);   Drug: Insulin glulisine (HMR1964)
Outcome Measures: Change from baseline in HbA1c;   Change from baseline in body weight;   Percentage of patients reaching HbA1c <7%;   Percentage of patients reaching HbA1c ≤6.5%;   Change in body weight from baseline;   Percentage of patients with no weight gain;   Change in 7-point SMPG profiles from baseline;   Change from baseline in FPG;   Change from baseline in post-prandial glucose /glucose excursions during a standardized meal test (subset of patients);   Change from baseline in Insulin glargine dose;   Daily dose of Insulin glulisine;   Total daily dose of Insulin;   Documented (PG <60 mg/dl) symptomatic hypoglycemia (percentage of subjects with at least one episode, number of events per patient-year);   Severe hypoglycemia